Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III

Sven Cichon, Ludovic Martin, Hans Christian Hennies, Felicitas Müller, Karen Van Driessche, Anna Karpushova, Wim Stevens, Roberto Colombo, Thomas Renné, Christian Drouet, Konrad Bork, Markus M. Nöthen

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels - for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C→A and c.1032C→G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor) as a possible cause of HAE type III. Here, we report the occurrence of the c.1032C→A (p.Thr328Lys) mutation in an HAE type III-affected family of French origin. Investigation of the F12 gene in a large German family did not reveal a coding mutation. Haplotype analysis with use of microsatellite markers is compatible with locus heterogeneity in HAE type III. To shed more light on the pathogenic relevance of the HAE type III-associated p.Thr328Lys mutation, we compared FXII activity and plasma levels in patients carrying the mutation with that of healthy control individuals. Our data strongly suggest that p.Thr328Lys is a gain-of-function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels. We conclude that enhanced FXII enzymatic plasma activity in female mutation carriers leads to enhanced kinin production, which results in angioedema. Transcription of F12 is positively regulated by estrogens, which may explain why only women are affected with HAE type III. The results of our study represent an important step toward an understanding of the molecular processes involved in HAE type III and provide diagnostic and possibly new therapeutic opportunities.

LanguageEnglish
Pages1098-1104
Number of pages7
JournalAmerican Journal of Human Genetics
Volume79
Issue number6
DOIs
Publication statusPublished - 1 Jan 2006
Externally publishedYes

Fingerprint

Hereditary Angioedema Type III
Factor XII
Mutation
Hereditary Angioedema Types I and II
Hereditary Angioedemas
Estrogens
Laryngeal Edema
Genes
Angioedema
Kinins
Missense Mutation
Oral Contraceptives
Microsatellite Repeats
Haplotypes
Abdominal Pain

Cite this

Cichon, S., Martin, L., Hennies, H. C., Müller, F., Van Driessche, K., Karpushova, A., ... Nöthen, M. M. (2006). Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III. American Journal of Human Genetics, 79(6), 1098-1104. https://doi.org/10.1086/509899
Cichon, Sven ; Martin, Ludovic ; Hennies, Hans Christian ; Müller, Felicitas ; Van Driessche, Karen ; Karpushova, Anna ; Stevens, Wim ; Colombo, Roberto ; Renné, Thomas ; Drouet, Christian ; Bork, Konrad ; Nöthen, Markus M. / Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III. In: American Journal of Human Genetics. 2006 ; Vol. 79, No. 6. pp. 1098-1104.
@article{838b469f45bd40abac50fb4cc45f2125,
title = "Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III",
abstract = "Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels - for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C→A and c.1032C→G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor) as a possible cause of HAE type III. Here, we report the occurrence of the c.1032C→A (p.Thr328Lys) mutation in an HAE type III-affected family of French origin. Investigation of the F12 gene in a large German family did not reveal a coding mutation. Haplotype analysis with use of microsatellite markers is compatible with locus heterogeneity in HAE type III. To shed more light on the pathogenic relevance of the HAE type III-associated p.Thr328Lys mutation, we compared FXII activity and plasma levels in patients carrying the mutation with that of healthy control individuals. Our data strongly suggest that p.Thr328Lys is a gain-of-function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels. We conclude that enhanced FXII enzymatic plasma activity in female mutation carriers leads to enhanced kinin production, which results in angioedema. Transcription of F12 is positively regulated by estrogens, which may explain why only women are affected with HAE type III. The results of our study represent an important step toward an understanding of the molecular processes involved in HAE type III and provide diagnostic and possibly new therapeutic opportunities.",
author = "Sven Cichon and Ludovic Martin and Hennies, {Hans Christian} and Felicitas M{\"u}ller and {Van Driessche}, Karen and Anna Karpushova and Wim Stevens and Roberto Colombo and Thomas Renn{\'e} and Christian Drouet and Konrad Bork and N{\"o}then, {Markus M.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1086/509899",
language = "English",
volume = "79",
pages = "1098--1104",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "6",

}

Cichon, S, Martin, L, Hennies, HC, Müller, F, Van Driessche, K, Karpushova, A, Stevens, W, Colombo, R, Renné, T, Drouet, C, Bork, K & Nöthen, MM 2006, 'Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III', American Journal of Human Genetics, vol. 79, no. 6, pp. 1098-1104. https://doi.org/10.1086/509899

Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III. / Cichon, Sven; Martin, Ludovic; Hennies, Hans Christian; Müller, Felicitas; Van Driessche, Karen; Karpushova, Anna; Stevens, Wim; Colombo, Roberto; Renné, Thomas; Drouet, Christian; Bork, Konrad; Nöthen, Markus M.

In: American Journal of Human Genetics, Vol. 79, No. 6, 01.01.2006, p. 1098-1104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased activity of coagulation factor XII (Hageman Factor) causes hereditary angioedema type III

AU - Cichon, Sven

AU - Martin, Ludovic

AU - Hennies, Hans Christian

AU - Müller, Felicitas

AU - Van Driessche, Karen

AU - Karpushova, Anna

AU - Stevens, Wim

AU - Colombo, Roberto

AU - Renné, Thomas

AU - Drouet, Christian

AU - Bork, Konrad

AU - Nöthen, Markus M.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels - for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C→A and c.1032C→G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor) as a possible cause of HAE type III. Here, we report the occurrence of the c.1032C→A (p.Thr328Lys) mutation in an HAE type III-affected family of French origin. Investigation of the F12 gene in a large German family did not reveal a coding mutation. Haplotype analysis with use of microsatellite markers is compatible with locus heterogeneity in HAE type III. To shed more light on the pathogenic relevance of the HAE type III-associated p.Thr328Lys mutation, we compared FXII activity and plasma levels in patients carrying the mutation with that of healthy control individuals. Our data strongly suggest that p.Thr328Lys is a gain-of-function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels. We conclude that enhanced FXII enzymatic plasma activity in female mutation carriers leads to enhanced kinin production, which results in angioedema. Transcription of F12 is positively regulated by estrogens, which may explain why only women are affected with HAE type III. The results of our study represent an important step toward an understanding of the molecular processes involved in HAE type III and provide diagnostic and possibly new therapeutic opportunities.

AB - Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels - for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C→A and c.1032C→G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor) as a possible cause of HAE type III. Here, we report the occurrence of the c.1032C→A (p.Thr328Lys) mutation in an HAE type III-affected family of French origin. Investigation of the F12 gene in a large German family did not reveal a coding mutation. Haplotype analysis with use of microsatellite markers is compatible with locus heterogeneity in HAE type III. To shed more light on the pathogenic relevance of the HAE type III-associated p.Thr328Lys mutation, we compared FXII activity and plasma levels in patients carrying the mutation with that of healthy control individuals. Our data strongly suggest that p.Thr328Lys is a gain-of-function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels. We conclude that enhanced FXII enzymatic plasma activity in female mutation carriers leads to enhanced kinin production, which results in angioedema. Transcription of F12 is positively regulated by estrogens, which may explain why only women are affected with HAE type III. The results of our study represent an important step toward an understanding of the molecular processes involved in HAE type III and provide diagnostic and possibly new therapeutic opportunities.

UR - http://www.scopus.com/inward/record.url?scp=33845219794&partnerID=8YFLogxK

U2 - 10.1086/509899

DO - 10.1086/509899

M3 - Article

VL - 79

SP - 1098

EP - 1104

JO - American Journal of Human Genetics

T2 - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 6

ER -